Back
Day Range
$449.14
$459.37
52-Week Range
$362.50
$513.98
Volume
1,172,499
50D / 200D Avg
$469.18
/
$438.51
Prev Close
$448.62
Quick Summary
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 29.2 | 0.3 |
| P/B | 6.2 | 3.0 |
| ROE % | 22.5 | 3.7 |
| Net Margin % | 32.7 | 3.8 |
| Rev Growth 5Y % | 12.4 | 10.0 |
| D/E | 0.2 | 0.2 |
Analyst Price Target
Hold
$549.73
+20.8%
Low: $441.00
High: $607.00
Forward P/E
23.55
Forward EPS
$19.32
EPS Growth (est.)
+0.0%
Est. Revenue
13.03B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$33.61
$31.04 – $37.27
|
19.79B | 5 |
| FY2029 |
$29.57
$27.31 – $32.79
|
17.85B | 11 |
| FY2028 |
$25.20
$14.13 – $35.75
|
15.99B | 13 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-12 | $5.11 | $5.03 | -1.6% |
| 2025-11-03 | $4.57 | $4.80 | +5.0% |
| 2025-08-04 | $4.29 | $4.52 | +5.4% |
| 2025-05-05 | $4.25 | $4.06 | -4.5% |
| 2025-02-10 | $4.02 | $3.98 | -1.0% |
| 2024-11-04 | $4.14 | $4.38 | +5.8% |
| 2024-08-01 | -$11.63 | -$12.83 | -10.3% |
| 2024-05-06 | $4.06 | $4.76 | +17.2% |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2026 |
Bozic Carmen
EVP and CMO
|
sell | 2,329 | $481.79 | $1,122,088.91 |
| Mar 2, 2026 |
Liu Joy
EVP and Chief Legal Officer
|
sell | 892 | $495.96 | $442,396.32 |
| Feb 25, 2026 |
Biller Jonathan
EVP and Chief Legal Officer
|
sell | 945 | $486.35 | $459,600.75 |
| Feb 25, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
sell | 4,910 | $486.35 | $2,394,365.00 |
| Feb 24, 2026 |
Biller Jonathan
EVP and Chief Legal Officer
|
other | 1,144 | $485.11 | $554,965.84 |
| Feb 24, 2026 |
LEIDEN JEFFREY M
Executive Chairman
|
other | 3,547 | $485.11 | $1,720,685.17 |
| Feb 24, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
other | 873 | $485.11 | $423,501.03 |
| Feb 24, 2026 |
Kewalramani Reshma
CEO & President
|
other | 4,981 | $485.11 | $2,416,332.91 |
| Feb 24, 2026 |
Bozic Carmen
EVP and CMO
|
other | 1,453 | $485.11 | $704,864.83 |
| Feb 17, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
grant | 4,962 | — | — |
| Feb 17, 2026 |
McKechnie Duncan
EVP, Chief Commercial Officer
|
other | 1,148 | $483.75 | $555,345.00 |
| Feb 13, 2026 |
Kewalramani Reshma
CEO & President
|
other | 13,041 | $487.76 | $6,360,878.16 |
| Feb 10, 2026 |
WAGNER CHARLES F JR
EVP, CO & FO
|
other | 3,045 | $468.41 | $1,426,308.45 |
| Feb 10, 2026 |
Sachdev Amit
EVP Chief Patient & Ext Af Off
|
other | 2,057 | $468.41 | $963,519.37 |
| Jan 22, 2026 |
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
|
grant | 11,749 | — | — |
| Jan 6, 2026 |
WAGNER CHARLES F JR
EVP, CO & FO
|
other | 19,064 | $189.38 | — |
| Jan 6, 2026 |
WAGNER CHARLES F JR
EVP, CO & FO
|
sell | 9,532 | $461.00 | $4,394,252.00 |
| May 1, 2025 |
SACHS BRUCE I
Director
|
grant | 2,398 | — | — |
| May 1, 2025 |
CARNEY LLOYD
Director
|
grant | 796 | — | — |
| Apr 15, 2025 |
SACHS BRUCE I
Director
|
grant | 95 | $497.51 | $47,263.45 |
Dividend History
Yield
0.00%
Payout Ratio
0.00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Key Takeaways
Revenue grew 12.37% annually over 5 years — strong growth
ROE of 22.54% indicates high profitability
Net margin of 32.74% shows strong profitability
Debt/Equity of 0.21 — conservative balance sheet
Generating 3.19B in free cash flow
Cash machine — converts 80.79% of earnings into free cash flow
Growth
Revenue Growth (5Y)
12.37%
Revenue (1Y)9.57%
Earnings (1Y)N/A
FCF Growth (3Y)-1.31%
Quality
Return on Equity
22.54%
ROIC15.84%
Net Margin32.74%
Op. Margin39.43%
Safety
Debt / Equity
0.21
Current Ratio2.90
Interest Coverage357.95
Valuation
P/E Ratio
29.23
Forward P/E23.36
P/B Ratio6.19
EV/EBITDA24.02
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9.57% | Revenue Growth (3Y) | 10.61% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | 4.51% |
| Revenue Growth (5Y) | 12.37% | Earnings Growth (5Y) | 13.98% |
| Profitability | |||
| Revenue (TTM) | 12.07B | Net Income (TTM) | 3.95B |
| ROE | 22.54% | ROA | 15.12% |
| Gross Margin | 85.03% | Operating Margin | 39.43% |
| Net Margin | 32.74% | Free Cash Flow (TTM) | 3.19B |
| ROIC | 15.84% | FCF Growth (3Y) | -1.31% |
| Safety | |||
| Debt / Equity | 0.21 | Current Ratio | 2.90 |
| Interest Coverage | 357.95 | ||
| Dividends | |||
| Dividend Yield | 0.00% | Payout Ratio | 0.00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 29.23 | Forward P/E | 23.36 |
| P/B Ratio | 6.19 | P/S Ratio | 9.57 |
| PEG Ratio | -0.03 | Forward PEG | N/A |
| EV/EBITDA | 24.02 | Fwd EV/EBITDA | 24.32 |
| Forward P/S | 8.87 | Fwd Earnings Yield | 4.28% |
| FCF Yield | 2.76% | ||
| Market Cap | 115.56B | Enterprise Value | 114.36B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 12.07B | 11.02B | 9.87B | 8.93B | 7.57B |
| Net Income | 3.95B | -535.60M | 3.62B | 3.32B | 2.34B |
| EPS (Diluted) | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 |
| Gross Profit | 10.27B | 9.49B | 8.61B | 7.85B | 6.67B |
| Operating Income | 4.76B | -232.90M | 3.83B | 4.31B | 2.78B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 26.14B | 22.53B | 22.73B | 18.15B | 13.43B |
| Total Liabilities | 7.48B | 6.12B | 5.15B | 4.24B | 3.33B |
| Shareholders' Equity | 18.67B | 16.41B | 17.58B | 13.91B | 10.10B |
| Total Debt | 3.88B | 1.75B | 808.40M | 899.70M | 967.40M |
| Cash & Equivalents | 5.09B | 4.57B | 10.37B | 10.50B | 6.80B |
| Current Assets | 11.20B | 9.60B | 14.14B | 13.23B | 9.56B |
| Current Liabilities | 3.86B | 3.56B | 3.55B | 2.74B | 2.14B |